| Literature DB >> 35334938 |
Pinta Marito1,2, Yoko Hasegawa1,3, Kayoko Tamaki4, Ma Therese Sta Maria1,5, Tasuku Yoshimoto1, Hiroshi Kusunoki4, Shotaro Tsuji6, Yosuke Wada7, Takahiro Ono1, Takashi Sawada8, Hiromitsu Kishimoto3, Ken Shinmura4.
Abstract
Hypertension is related to impaired mastication that causes malnutrition, declining the general health of older adults. This study assessed the role of dietary intake in the relationship between oral health and blood pressure. Eight hundred ninety-four adults aged ≥65 years who independently lived in rural regions of Japan participated in this study. Hypertension was classified according to the guidelines of the Japanese Society of Hypertension. The oral condition was evaluated by analyzing the remaining teeth, occlusal force, posterior occlusal support, masticatory performance, oral moisture, and oral bacterial level. Dietary intake was assessed using a brief self-administered dietary history questionnaire. Mann-Whitney U, chi-square, Kruskal-Wallis tests, and logistic regression analyses were used to elucidate the factors related to hypertension. Normotensive, hypertensive, and history of hypertension were observed in 30.9%, 23.8%, and 45.3% of the participants, respectively. The factors significantly associated with the hypertension were age, body mass index, posterior occlusal support condition, and sodium-to-potassium ratio related to salt intake and/or vegetable intake. Participants without posterior occlusion significantly had higher risk of hypertension (odds ratio = 1.72). This study suggested that there was an association between oral health and hypertension, while the loss of occlusal support may influence nutritional intake conditions.Entities:
Keywords: blood pressure; brief-type self-administered diet history questionnaire; dietary intake; hypertension; oral health
Mesh:
Year: 2022 PMID: 35334938 PMCID: PMC8950359 DOI: 10.3390/nu14061279
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram demonstrating the recruitment and group assignment of the study participants. BDHQ; a brief self-administered diet history questionnaire. Normotensive: Participants with systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg, Hypertensive: Participants with SBP of ≥140 mmHg and/or DBP ≥ 90 mmHg, History of hypertension: Participants who answered that they had a history of hypertension in the medical interview and/or is taking hypertension medication.
List of the Antihypertensive medications.
| Number of Participants | Drug’s Name | Generic Name | Therapeutic Category | Drug Classification |
|---|---|---|---|---|
| 13 | Amlodipine Tablets | Amlodipine Besilate | Long-acting calcium antagonist | calcium channel blockers |
| 6 | Micardis Tablets | Telmisartan | Bile excretion type persistent AT1 receptor blocker | angiotensin II receptor blocker |
| 5 | Blopress Tablets | Candesartan Cilexetil | Long-acting angiotensin II receptor blocker | Beta blocker |
| 1 | Bisoprolol Fumarate | Bisoprolol Fumarate | Selective β1 antagonist | Beta blocker |
| 2 | Candesartan | Candesartan Cilexetil | Long-acting angiotensin II receptor blocker | angiotensin II receptor blocker |
| 4 | Diovan OD Tablets | Valsartan | Selective AT1 receptor blocker | angiotensin II receptor blockers |
| 1 | Losartan Potassium Tablets | Losartan Potassium | Angiotensin II antagonist | angiotensin II receptor blocker |
| 3 | Azilva Tablets | Azilsartan | Long-acting AT1 receptor blocker | angiotensin II receptor blocker |
| 4 | Norvasc Tablets | Amlodipine Besilate | Long-acting calcium antagonist | calcium channel blockers |
| 3 | Unisia Combination Tablets | Candesartan CilexetilAmlodipine Besilate | Long-acting angiotensin II receptor blocker/Long-acting calcium antagonist | angiotensin II receptor blocker |
| 3 | Coniel Tablets | Benidipine Hydrochloride | Long-acting calcium antagonist | calcium channel blocker |
| 2 | Camcia Combination Tablets Ld | Candesartan Cilexetil, Amlodipine Besilate | Long-acting angiotensin II receptor blocker/Long-acting calcium antagonist | persistent angiotensin II receptor blocker/persistent calcium antagonist combination drug |
| 2 | Irbetan Tablets | Irbesartan | Long-acting angiotensin II receptor blocker | angiotensin II receptor blocker |
| 1 | Cardenalin Tablets | Doxazosin Mesilate | Alpha1 adrenoceptor antagonist | α 1 blocker |
| 2 | Olmetec OD Tablets | Olmesartan Medoxomil | High affinity AT1-receptor antagonist | angiotensin II receptor blocker |
| 2 | Nu-Lotan Tablets | Losartan Potassium | Angiotensin II antagonist | angiotensin II receptor blocker |
| 1 | Avapro Tablets | Irbesartan | Long-acting angiotensin II receptor blocker | angiotensin II receptor blocker |
| 1 | Ecard Combination Tablets | Candesartan CilexetilHydrochlorothiazide | Long-acting angiotensin II receptor blocker/Diuretic Combination agent | angiotensin II receptor blocker |
| 1 | Renivace Tablets | Enalapril Maleate | Long-acting angiotensin-converting enzyme inhibitor | angiotensin converting enzyme inhibitor |
| 1 | Teramuro Combination Tablets | Telmisartan, Amlodipine Besilate | Bile excretion type long-acting AT1 receptor blocker/Long-acting calcium antagonist | calcium channel blockers |
| 1 | Telmisartan Tablets | Telmisartan | Bile excretion type long-acting AT1 receptor blocker | angiotensin II receptor blocker |
| 1 | Adalat-L | Nifedipine | Long-acting calcium antagonist | calcium channel blocker |
| 1 | Herbesser Tablets | Diltiazem Hydrochloride | calcium antagonist | calcium channel blocker |
| 1 | Selara Tablets | Eplerenone | Selective aldosterone blocker | aldosterone receptor antagonists |
| 1 | Spironolactone Tablets | Spironolactone | Anti-aldosterone diuresis | aldosterone receptor antagonists |
AT1: Angiotensin II type 1. Hypertension medications were collected based on the medical interview gathered from the participants’ information.
List of two combinations of antihypertensive drugs.
| Number of Participants | Drug’s Name |
|---|---|
| 1 | Amlodipine Tablets and Losartan Potassium Tablets |
| 2 | Amlodipine Tablets and Micardis Tablets |
| 1 | Amlodipine Tablets and Candesartan |
| 1 | Diovan OD Tablets and Norvasc Tablets |
| 1 | Azilva Tablets and Norvasc Tablets |
| 1 | Norvasc Tablets and Cardenalin Tablets |
| 1 | Coniel Tablets and Spironolactone Tablets |
OD: Orally Disintegrating. Hypertension medications were collected based on the medical interview gathered from the participants’ information.
Figure 2Classification of the Posterior Occlusal Contact: (A) With posterior occlusion (with PO) group consisting of Eichner A1, A2, A3, B1, B2, and B3; (B) Without Posterior occlusion (without PO) group consisting of Eichner B4, C1, and C2 [52]; (C) the edentulous group [53].
Subject characteristics.
| Measurement Variables | Total ( | Normotensive Group ( | Hypertensive Group ( | History of Hypertension Group ( | Two-Group Comparison | |
|---|---|---|---|---|---|---|
| Age (Years) * | 74.3 ± 0.2 | 73.3 ± 0.3 | 74.3 ± 0.4 | 75.0 ± 0.3 | 0.002 | b |
| Sex ** | ||||||
| Male | 282 (31.5) | 82 (29.7) | 56 (26.3) | 144 (35.6) | 0.046 | c |
| Female | 612 (68.5) | 194 (70.3) | 157 (73.7) | 261 (64.4) | ||
| Education (years) | 12.4 ± 0.1 | 12.4 ± 0.1 | 12.4 ± 0.1 | 12.3 ± 0.1 | 0.80 | |
| Living arrangement | ||||||
| Alone | 98 (14.1) | 33 (15.1) | 24 (14.5) | 41 (13.3) | 0.83 | |
| With Family | 596 (85.9) | 186 (84.9) | 142 (85.5) | 268 (86.7) | ||
| Exercise habits | 524 (58.7) | 178 (64.5) | 120 (56.3) | 226 (55.8) | 0.06 | |
| Exercise Frequency (times) | 14.1 ± 0.5 | 14.4 ± 0.8 | 12.6 ± 0.9 | 14.7 ± 0.7 | 0.29 | |
| Exercise periods (years) | 11.4 ± 0.7 | 10.9 ± 1.1 | 11.8 ± 1.5 | 11.7 ± 1.2 | 0.88 | |
| Alcohol Consumption (g/day) | 7.3 ± 0.5 | 6.0 ± 15.7 | 5.9 ± 0.9 | 8.8 ± 0.9 | 0.32 | |
| Current or past smoking habit ** | 247 (27.6) | 71 (25.7) | 48 (22.5) | 128 (31.6) | 0.039 | |
| Blood Pressure | ||||||
| Systole (mmHg) * | 139.3 ± 0.6 | 126.8 ± 0.6 | 152.8 ± 0.9 | 140.7 ± 0.9 | <0.001 | a b c |
| Diastole (mmHg) * | 80.0 ± 0.4 | 73.5 ± 0.5 | 87.0 ± 0.6 | 80.8 ± 0.5 | <0.001 | a b c |
| Pulse Pressure (mmHg) * | 59.3 ± 0.4 | 53.4 ± 0.5 | 65.8 ± 0.7 | 59.9 ± 0.6 | <0.001 | a b c |
| Body Composition | ||||||
| BMI (kg/m2) * | 22.7 ± 0.1 | 21.7 ± 0.2 | 22.8 ± 0.2 | 23.3 ± 0.1 | <0.001 | a b |
| Skeletal Muscle Mass (kg) * | 21.0 ± 0.1 | 20.6 ± 0.2 | 20.4 ± 0.3 | 21.6 ± 0.2 | 0.003 | b c |
| Body Fat Mass (kg) * | 15.4 ± 0.2 | 13.9 ± 0.3 | 15.8 ± 0.4 | 16.1 ± 0.3 | <0.001 | a b |
| Percent Body Fat * | 27.8 ± 0.3 | 26.3 ± 0.4 | 28.8 ± 0.5 | 28.4 ± 0.4 | <0.001 | a b |
| Comorbidity Disease | ||||||
| Diabetes mellitus | 107 (12.0) | 29 (10.5) | 20 (9.4) | 55 (13.6) | 0.55 | |
| Dyslipidemia | 208 (23.3) | 58 (21.0) | 51 (23.9) | 99 (24.4) | 0.56 | |
| Chronic kidney disease | 27(3.0) | 5 (1.8) | 8 (3.8) | 14 (3.5) | 0.36 | |
| Cardiovascular disease (CVD) ** | 61 (6.8) | 17 (6.2) | 7 (3.3) | 37 (9.1) | 0.020 | |
| Stroke ** | 12 (1.3) | 1 (0.4) | 1 (0.5) | 10 (2.5) | 0.029 |
Data are presented as mean ± standard error or number of participants (%). The significance level was set at p < 0.05. *: Significant differences were seen using the Kruskal-Wallis Test, **: Significant differences were seen using the X2-test. BMI: body mass index; Normotensive: Participants with systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg; Hypertensive: Participants with SBP of ≥140 mmHg and/or DBP ≥ 90 mmHg; History of hypertension: Participants who answered that they had a history of hypertension in the medical interview and/or is taking hypertension medication; Exercise habits: participants who regularly exercise; exercise frequency: the frequency of exercise every month; exercise periods: the number of years the participants have been exercising. Current or past smoking habits: Participants who smoked or had a smoking history. The Mann-Whitney U-test with Bonferroni correction was used to compare the two groups: a: statistically significant difference between the Normotensive and the Hypertensive groups; b: statistically significant difference between the Normotensive and History of hypertension groups; c: statistically significant difference between the Hypertensive and History of hypertension groups.
The Relationship Between Oral Health and Hypertension.
| Variables | Total ( | Normotensive Group ( | Hypertensive Group ( | History of Hypertension Group ( | Two-Group Comparison | |
|---|---|---|---|---|---|---|
| Remaining teeth (teeth) * | 19.8 ± 0.3 | 21.2 ± 0.5 | 19.6 ± 0.6 | 19.1 ± 0.5 | 0.007 | b |
| Maximum Occlusal force (kgf) | 51.1 ± 1.3 | 53.5 ± 2.3 | 51.4 ± 2.5 | 49.2 ± 1.9 | 0.27 | |
| Masticatory Performance (score) * | 4.0 ± 0.1 | 4.3 ± 0.1 | 3.7 ± 0.2 | 3.9 ± 0.1 | 0.004 | a b |
| Posterior occlusal contact ** | 0.012 | b | ||||
| With posterior occlusion (w/PO) | 671 (75.1) | 226 (81.9) | 159 (74.6) | 286 (70.6) | ||
| Without posterior occlusion (w/o PO) | 160 (17.9) | 32 (11.6) | 39 (18.3) | 89 (22.0) | ||
| Edentulous | 63 (7.0) | 18 (6.5) | 15 (7.0) | 30 (7.4) | ||
| Oral Moisture | ||||||
| Cheek | 28.4 ± 0.2 | 28.5 ± 0.2 | 28.6 ± 0.7 | 28.2 ± 0.2 | 0.42 | |
| Tongue | 26.8 ± 0.1 | 27.1 ± 0.2 | 26.6 ± 0.3 | 26.8 ± 0.2 | 0.45 | |
| Total mucus | 55.2 ± 0.3 | 55.6 ± 0.4 | 55.2 ± 0.9 | 55.0 ± 0.4 | 0.43 | |
| Bacterial count (CFU/mL) | 4.6 × 107 ± 1.7 × 107 | 6.6 × 107 ± 4.3 × 107 | 2.3 × 107 ± 3 × 106 | 4.6 × 107 ± 2.3 × 107 | 0.83 | |
| Bacterial level (min. max: 1. 7) | 4.8 ± 0.03 | 4.8 ± 0.1 | 4.8 ± 0.1 | 4.8 ± 0.04 | 0.97 |
Data are presented as mean ± standard error or number of participants (%). The significance level was set at p < 0.05. * Significant differences were seen using the Kruskal-Wallis test; **: Significant differences were seen using the X2-test. kgf: kilogram-force, CFU: colony-forming unit, min: minimum, max: maximum. Posterior occlusal contact was classified into three groups according to the availability of posterior teeth based on the Eichner index. With posterior occlusion (with/PO) group consisting of Eichner A1, A2, A3, B1, B2, and B3; Without Posterior occlusion (w/o PO) group consisting of Eichner B4, C1, and C2; the edentulous group consisting of Eichner C3 [19]. The Mann-Whitney U-test with Bonferroni correction was used to compare the two groups: a: statistically significant difference between the Normotensive and the Hypertensive groups; b: statistically significant difference between the Normotensive and History of hypertension groups; c: statistically significant difference between the Hypertensive and History of hypertension groups.
Comparison of nutrient and dietary intake among groups.
| Variables | Total ( | Normotensive Group ( | Hypertensive Group ( | History of Hypertension Group ( | Two-Group Comparison | |
|---|---|---|---|---|---|---|
| Nutrient Intake | ||||||
| Energy (kcal/day) | 2083.8 ± 21.4 | 2080.1 ± 38.0 | 2099.6 ± 46.2 | 2078.0 ± 31.1 | 0.97 | |
| Carbohydrates (g/day) | 263.6 ± 2.9 | 263.8 ± 5.2 | 265.2 ± 6.1 | 262.6 ± 4.3 | 0.99 | |
| Protein Total (g/day) | 90.8 ± 1.2 | 91.1 ± 2.1 | 92.5 ± 2.6 | 89.8 ± 1.7 | 0.93 | |
| Animal | 56.5 ± 0.9 | 56.0 ± 1.6 | 58.2 ± 2.1 | 56.1 ± 1.4 | 0.96 | |
| Vegetable | 34.3 ± 0.4 | 35.1 ± 0.7 | 34.3 ± 0.8 | 33.8 ± 0.5 | 0.47 | |
| Fat Total (g/day) | 66.1 ± 0.8 | 66.6 ± 1.4 | 67.4 ± 1.8 | 65.1 ± 1.2 | 0.65 | |
| Animal | 32.3 ± 0.5 | 32.3 ± 0.8 | 33.1 ± 1.1 | 31.8 ± 0.7 | 0.83 | |
| Vegetable | 33.9 ± 0.4 | 34.4 ± 0.8 | 34.3 ± 0.9 | 33.3 ± 0.6 | 0.59 | |
| Sodium (mg/day) | 4994.3 ± 59.5 | 4950.0 ± 103.6 | 5082.4 ± 130.4 | 4978.3 ± 87.1 | 0.95 | |
| Potassium (mg/day) | 3392.7 ± 44.0 | 3506.1 ± 81.0 | 3382.5 ± 92.9 | 3320.7 ± 63.0 | 0.34 | |
| Sodium-to-Potassium Ratio * | 1.55 ± 0.01 | 1.48 ± 0.02 | 1.56 ± 0.03 | 1.58 ± 0.02 | 0.002 | a b |
| Calcium (mg/day) | 806.0 ± 11.5 | 828.9 ± 21.2 | 797.2 ± 24.0 | 795.0 ± 16.7 | 0.39 | |
| Magnesium (mg/day) | 329.4 ± 4.1 | 337.4 ± 7.5 | 329.4 ± 8.7 | 323.9 ± 5.8 | 0.51 | |
| Fatty Acids (g/day) | ||||||
| Saturated | 17.8 ± 0.2 | 18.0 ± 0.4 | 18.2 ± 0.5 | 17.5 ± 0.3 | 0.51 | |
| Monounsaturated | 23.2 ± 0.3 | 23.3 ± 0.5 | 23.8 ± 0.6 | 22.8 ± 0.4 | 0.56 | |
| Polyunsaturated | 15.7 ± 0.2 | 15.9 ± 0.3 | 15.9 ± 0.4 | 15.5 ± 0.3 | 0.79 | |
| Dietary Fiber (g/day) | 15.6 ± 0.2 | 16.2 ± 0.4 | 15.6 ± 0.4 | 15.2 ± 0.3 | 0.33 | |
| Water-Soluble | 4.0 ± 0.1 | 4.1 ± 0.1 | 3.9 ± 0.1 | 3.9 ± 0.1 | 0.29 | |
| Insoluble | 11.1 ± 0.1 | 11.5 ± 0.3 | 11.1 ± 0.3 | 10.8 ± 0.2 | 0.29 | |
| β-carotene (μg/day) * | 5331.5 ± 103.5 | 5760.4 ± 206.3 | 5251.8 ± 200.0 | 5081.2 ± 145.1 | 0.07 | b |
| Retinol (mg/day) | 1064.4 ± 24.8 | 1115.0 ± 45.7 | 1015.2 ± 50.1 | 1055.3 ± 36.5 | 0.41 | |
| Vit. B1 (mg/day) | 1.0 ± 0.0 | 1.0 ± 0.0 | 1.0 ± 0.0 | 1.0 ± 0.0 | 0.55 | |
| Vit. B2 (mg/day) | 1.7 ± 0.0 | 1.8 ± 0.0 | 1.7 ± 0.0 | 1.7 ± 0.0 | 0.24 | |
| Niacin (mg/day) | 21.8 ± 0.3 | 21.9 ± 0.5 | 22.1 ± 0.7 | 21.5 ± 0.5 | 0.87 | |
| Vit. B6 (mg/day) | 1.7 ± 0.0 | 1.7 ± 0.0 | 1.7 ± 0.0 | 1.6 ± 0.0 | 0.73 | |
| Vit. B12 (μg/day) | 14.5 ± 0.3 | 14.1 ± 0.5 | 14.5 ± 0.6 | 14.8 ± 0.5 | 0.78 | |
| Folate (μg/day) | 470.9 ± 6.5 | 492.0 ± 11.9 | 466.4 ± 13.3 | 458.8 ± 9.4 | 0.12 | |
| Pantothenic Acid (mg/day) | 8.3 ± 0.1 | 8.4 ± 0.2 | 8.3 ± 0.2 | 8.2 ± 0.1 | 0.75 | |
| Vit. C (mg/day) | 167.3 ± 2.7 | 172.0 ± 4.9 | 167.8 ± 5.5 | 163.7 ± 4.0 | 0.51 | |
| Vit. D (μg/day) | 24.6 ± 0.6 | 24.3 ± 1.0 | 25.1 ± 1.3 | 24.6 ± 0.9 | 0.99 | |
| Vit. K (μg/day) * | 425.1 ± 7.6 | 451.8 ± 14.3 | 425.5 ± 15.8 | 406.7 ± 10.8 | 0.07 | b |
| Food Groups (g/day) | ||||||
| Cereals | 371.2 ± 5.5 | 367.1 ± 9.5 | 374.9 ± 11.1 | 372.1 ± 8.6 | 0.85 | |
| Potatoes | 65.8 ± 1.9 | 68.2 ± 3.6 | 62.4 ± 3.7 | 66.0 ± 2.9 | 0.59 | |
| Sugars and sweeteners | 6.1 ± 0.1 | 6.0 ± 0.3 | 6.4 ± 0.3 | 5.9 ± 0.2 | 0.66 | |
| Legume | 89.9 ± 1.7 | 96.1 ± 3.5 | 86.3 ± 3.5 | 87.6 ± 2.3 | 0.23 | |
| Green and yellow vegetables * | 143.2 ± 2.9 | 154.5 ± 5.5 | 139.8 ± 5.9 | 137.3 ± 4.1 | 0.06 | b |
| Other vegetables | 221.6 ± 4.0 | 232.7 ± 7.6 | 220.3 ± 8.2 | 214.6 ± 5.7 | 0.21 | |
| Fruits | 162.1 ± 4.1 | 157.3 ± 6.7 | 165.0 ± 7.9 | 163.9 ± 6.5 | 0.74 | |
| Seafood | 125.5 ± 3.0 | 122.1 ± 5.0 | 128.5 ± 6.5 | 126.3 ± 4.4 | 0.90 | |
| Meat * | 80.6 ± 1.7 | 79.1 ± 2.9 | 88.9 ± 3.8 | 77.3 ± 2.4 | 0.03 | c |
| Eggs | 49.9 ± 1.1 | 50.2 ± 1.8 | 48.8 ± 2.0 | 50.3 ± 1.7 | 0.76 | |
| Dairy Products (Milk) | 184.4 ± 4.0 | 194.9 ± 7.7 | 172.7 ± 8.0 | 183.5 ± 5.7 | 0.24 | |
| Fats and oils | 11.5 ± 0.2 | 11.4 ± 0.3 | 11.9 ± 0.4 | 11.3 ± 0.3 | 0.48 | |
| Confectionery | 69.3 ± 1.9 | 68.6 ± 3.4 | 71.3 ± 4.1 | 68.7 ± 2.6 | 0.85 | |
| Beverages | 703.6 ± 11.8 | 737.3 ± 22.1 | 688.3 ± 24.4 | 688.7 ± 16.8 | 0.21 | |
| Condiments | 226.3 ± 5.0 | 224.5 ± 9.4 | 236.6 ± 10.6 | 222.1 ± 6.9 | 0.56 | |
| Salt Intake | 12.6 ± 0.2 | 12.5 ± 0.3 | 12.8 ± 0.3 | 12.6 ± 0.2 | 0.95 |
Dietary assessment is the result of a brief self-administered diet history questionnaire (BDHQ). The results are expressed as the mean ± standard error. The significance level was set to p < 0.1. The sodium-to-potassium ratio was defined as the amount of sodium consumed divided by the amount of potassium consumed [40,57], Vit.: Vitamin. * Significant differences were observed using the Kruskal-Wallis test. Mann-Whitney′s U-test with Bonferroni correction was used to compare the two groups: a: statistically significant difference between the Normotensive and the Hypertensive group; b: statistically significant difference between the Normotensive and the History of hypertension group; c: statistically significant difference between the Hypertensive group and the History of hypertension group.
Comparison of nutrient and dietary intake among groups by Sex.
| Measurement Variables | Normotensive Group ( | Hypertensive Group ( | History of Hypertension ( | Two-Group Comparison | |
|---|---|---|---|---|---|
| Male | |||||
| Age (Years) | 74.7 ± 0.7 | 75.0 ± 0.8 | 74.9 ± 0.5 | 0.9 | b |
| Blood Pressure | |||||
| Systole (mmHg) * | 125.8 ± 1.1 | 149.7 ± 1.5 | 138.7 ± 1.4 | <0.001 | a b c |
| Diastole (mmHg) * | 73.1 ± 0.8 | 86.0 ± 1.1 | 79.6 ± 1.0 | <0.001 | a b c |
| Pulse Pressure (mmHg) * | 52.7 ± 0.9 | 63.7 ± 1.3 | 59.1 ± 1.0 | <0.001 | a b c |
| Body Composition | |||||
| BMI (kg/m2) * | 22.1 ± 0.3 | 23.4 ± 0.3 | 23.7 ± 0.2 | <0.001 | a b |
| Skeletal Muscle Mass (kg) * | 25.5 ± 0.3 | 25.3 ± 0.5 | 26.5 ± 0.3 | 0.02 | c |
| Body Fat Mass (kg) * | 12.9 ± 0.6 | 15.4 ± 0.7 | 15.2 ± 0.5 | <0.001 | a b |
| Percent Body Fat * | 21.2 ± 0.7 | 24.5 ± 0.8 | 23.4 ± 0.5 | 0.002 | a b |
| Comorbidity Disease | |||||
| Cardiovascular disease | 11 (13.4) | 1 (1.8) | 18 (12.5) | 0.06 | |
| Stroke | 1 (1.2) | 1 (1.8) | 7 (4.9) | 0.26 | |
| Current or past smoking habits | 71 (25.7) | 48 (22.5) | 128 (31.6) | 0.17 | |
| Nutrient and Food Groups | |||||
| Sodium-to-potassium ratio * | 1.6 ± 0.1 | 1.8 ± 0.1 | 1.7 ± 0.04 | 0.01 | a |
| β-carotene (μg/day) | 5058.5 ± 308.6 | 4543.2 ± 380.5 | 4764.5 ± 241.3 | 0.47 | |
| Vit. K (μg/day) | 443.1 ± 26.2 | 397.0 ± 30.2 | 427.0 ± 19.9 | 0.52 | |
| Green and yellow vegetables (g/day) | 137.7 ± 8.7 | 124.0 ± 11.4 | 131.9 ± 6.9 | 0.53 | |
| Meat (g/day) | 77.0 ± 4.9 | 83.6 ± 6.6 | 75.3 ± 4.2 | 0.53 | |
| Female | |||||
| Age (Years) * | 72.8 ± 0.4 | 74.0 ± 0.4 | 75.1 ± 0.4 | <0.001 | b |
| Blood Pressure | |||||
| Systole (mmHg) * | 127.2 ± 0.7 | 153.9 ± 1.0 | 141.8 ± 1.2 | <0.001 | a b c |
| Diastole (mmHg) * | 73.6 ± 0.5 | 87.3 ± 0.8 | 81.5 ± 0.6 | <0.001 | a b c |
| Pulse Pressure (mmHg) * | 53.7 ± 0.5 | 66.6 ± 0.9 | 60.3 ± 0.7 | <0.001 | a b c |
| Body Composition | |||||
| BMI (kg/m2) * | 21.5 ± 0.2 | 22.6 ± 0.2 | 23.1 ± 0.2 | <0.001 | a b |
| Skeletal Muscle Mass (kg) | 18.5 ± 0.1 | 18.7 ± 0.1 | 18.8 ± 0.1 | 0.32 | |
| Body Fat Mass (kg) * | 14.4 ± 0.4 | 16.0 ± 0.4 | 16.7 ± 0.3 | <0.001 | a b |
| Percent Body Fat * | 28.4 ± 0.5 | 30.3 ± 0.6 | 31.2 ± 0.4 | <0.001 | a b |
| Comorbidity Disease | |||||
| Cardiovascular disease | 6 (3.1) | 6 (3.8) | 19 (7.3) | 0.09 | |
| Stroke | 0 | 0 | 3 (1.1) | 0.13 | |
| Current or past smoking habits | 71 (25.7) | 48 (22.5) | 128 (31.6) | 0.22 | |
| Nutrient and Food Groups | |||||
| Sodium to potassium ratio | 1.4 ± 0.0 | 1.5 ± 0.0 | 1.5 ± 0.0 | 0.08 | |
| β-carotene (μg/day) | 6057.1 ± 260.4 | 5504.6 ± 232.4 | 5255.9 ± 181.0 | 0.13 | |
| Vit. K (μg/day) | 455.5 ± 17.2 | 435.7 ± 18.5 | 395.5 ± 12.6 | 0.05 | b |
| Green and yellow vegetables (g/day) | 161.6 ± 6.9 | 145.4 ± 6.8 | 140.3 ± 5.2 | 0.09 | |
| Meat (g/day) | 80.0 ± 3.5 | 90.7 ± 4.6 | 78.3 ± 3.0 | 0.08 |
Data are presented as mean ± standard error or number of participants (%). The significance level was set at p < 0.1. *: Significant differences were seen using the Kruskal-Wallis Test. BMI: body mass index; Vit.: Vitamin; the Normotensive: Participants with systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg; Hypertensive: Participants with SBP of ≥140 mmHg and/or DBP ≥ 90 mmHg; History of hypertension: Participants who answered that they had a history of hypertension in the medical interview and/or is taking hypertension medication; Current or past smoking habits: Participants who smoked or had a history of smoking. The sodium-to-potassium ratio was defined as the amount of sodium consumed divided by the amount of potassium consumed [40,57]. The Mann-Whitney U-test with Bonferroni correction was used to compare the two groups: a: statistically significant difference between the Normotensive group and the Hypertensive group; b: Statistically significant difference between the Normotensive and the History of hypertension groups; c: Statistically significant difference between the Hypertensive and the History of hypertension groups.
Relationship among nutrient, food items, and oral health.
| Variables | Age | Remaining Teeth | Masticatory Performance | |||
|---|---|---|---|---|---|---|
| Overall |
|
|
| |||
| Sodium-to-potassium ratio | 0.04 | 0.23 | −0.07 * | 0.03 | −0.09 * | 0.01 |
| β-carotene | 0.10 ** | 0.003 | 0.04 | 0.28 | 0.03 | 0.46 |
| Vitamin K | 0.16 ** | <0.001 | 0.02 | 0.61 | 0.03 | 0.45 |
| Green and yellow vegetables | 0.12 ** | <0.001 | 0.03 | 0.32 | 0.03 | 0.38 |
| Meat | 0.09 ** | 0.006 | 0.02 | 0.51 | 0.01 | 0.82 |
| Normotensive group | ||||||
| Sodium-to-potassium ratio | 0.08 | 0.16 | −0.05 | 0.36 | −0.10 | 0.09 |
| β-carotene | 0.11 | 0.08 | 0.01 | 0.92 | 0.03 | 0.63 |
| Vitamin K | 0.19 ** | 0.001 | −0.02 | 0.69 | −0.02 | 0.73 |
| Green and yellow vegetables | 0.08 | 0.17 | 0.01 | 0.92 | 0.05 | 0.38 |
| Meat | 0.20 ** | 0.001 | 0.01 | 0.87 | 0.00 | 0.95 |
| Hypertensive group | ||||||
| Sodium-to-potassium ratio | −0.03 | 0.62 | −0.08 | 0.26 | −0.03 | 0.66 |
| β-carotene | 0.15 * | 0.03 | 0.03 | 0.68 | 0.02 | 0.83 |
| Vitamin K | 0.15 * | 0.03 | 0.03 | 0.67 | 0.02 | 0.74 |
| Green and yellow vegetables | 0.15 * | 0.03 | 0.05 | 0.43 | 0.02 | 0.74 |
| Meat | 0.03 | 0.61 | 0.06 | 0.37 | 0.07 | 0.34 |
| History of hypertension group | ||||||
| Sodium-to-potassium ratio | 0.01 | 0.79 | −0.05 | 0.31 | −0.07 | 0.16 |
| β-carotene | 0.09 | 0.07 | 0.04 | 0.43 | 0.01 | 0.83 |
| Vitamin K | 0.18 ** | <0.001 | 0.02 | 0.64 | 0.04 | 0.40 |
| Green and yellow vegetables | 0.15 ** | 0.002 | 0.02 | 0.67 | 0.00 | 0.97 |
| Meat | 0.05 | 0.31 | 0.01 | 0.89 | 0.00 | 0.94 |
r: Spearman correlation coefficient, *: p < 0.05, **: p < 0.001.
Factors affecting hypertension.
| Variables | B | Standard Error | Wald | Odds Ratio | 95% CI | ||
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| Age (Years) * | 0.04 | 0.02 | 6.98 | 0.01 | 1.04 | 1.01 | 1.07 |
| BMI (kg/m2) * | 0.20 | 0.03 | 45.19 | <0.001 | 1.23 | 1.16 | 1.30 |
| posterior occlusal contact | |||||||
| With posterior occlusion (w/PO) * | – | – | 6.15 | 0.05 | ref | – | – |
| Without posterior occlusion (w/o PO) * | 0.55 | 0.23 | 5.86 | 0.02 | 1.73 | 1.11 | 2.69 |
| Edentulous | −0.06 | 0.33 | 0.03 | 0.86 | 0.94 | 0.49 | 1.80 |
| Sodium-to-potassium ratio * | 0.50 | 0.20 | 6.34 | 0.01 | 1.65 | 1.12 | 2.43 |
| intercept | −7.45 | 1.31 | 32.18 | <0.001 | 0.001 | ||
Binary logistic regression analyses with stepwise methods (input: 0.05; removal: 0.15). Nagelkerke R2 = 0.125. Only the variables in the equation are presented. Hypertension, defined as participants belonging to the Hypertensive or the History of hypertension groups, was considered the objective variable (normotensive participants = 0, Hypertensive or History of hypertension participants = 1). The variables in Table 1, Table 2 and Table 3, which were significantly associated with hypertension, were entered as explanatory variables. B: Unstandardized coefficient; CI: 95% confidence interval for unstandardized coefficients. * Statistically significant explanatory variables, p < 0.1.